Recent publications


List of VHPB publications online available

Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report.
David FitzSimons, Greet Hendrickx, Johannes Hallauer, Heidi Larson, Daniel Lavanchy, Ina Lodewyckx,Daniel Shouval, John Ward and Pierre Van Damme.
Hepatology, Medicine and Policy; 2016, 1:16. DOI 10.1186/s41124-016-0022-8
Editorial on "What is a potentially damaging vaccination delay in children younger than 2 years?"
Kane MA, Roudot-Thoraval F, Guerin N, Papaevangelou V, Van Damme P; Viral Hepatitis Prevention Board.
Hum Vaccin Immunother. 2016 Aug 2;12(8):2053-2056.

Recent newsletters


VHPB Newsletter

Prevention and control of viral hepatitis in the Baltic States: lessons learnt and the way forward
Newsletter 2/2016 - June/2016  Riga, Latvia 463 kB (.pdf)
Towards a hepatitis-free Europe: how to make it feasible and affordable
Newsletter 1/2016 - January/2016  London, United Kingdom 725 kB (.pdf)
Burden and prevention of viral hepatitis in Arctic region
Vol. 21.1 - Mar/2012  Copenhagen, Denmark 808 kB (.pdf)

News - 28 July 2017 World Hepatitis Day

28 July is World Hepatitis Day. The theme for 2017 is #ShowYourFace to eliminate hepatitis:

To encourage people to feel empowered, personally connected and understand their role in elimination, this year, the ELIMINATE HEPATITIS theme is brought to life through the #ShowYourFace campaign.



News - WHA Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C

The members of the Executive Board of the World Hepatitis Alliance (WHA) have written an open letter to the Cochrane Collaboration in which they raise doubts about the recent Cochrane review of direct-acting antivirals (DAAs) for the treatment of hepatitis C. The WHA points to the unsound methodology leading to unreliable conclusions. 


News - EASL Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C

EASL, the European Association for the Study of the Liver, one of the leading associations of liver specialists, raises serious concerns after the recent publication of a Cochrane Group systematic review entitled “Direct acting antivirals for chronic hepatitis C” by Jakobsen et al. After reviewing 138 clinical trials, including 25,232 participants.


News - WHO Global hepatitis report, 2017

In May 2016, the World Health Assembly endorsed the Global Health Sector Strategy (GHSS) on viral hepatitis 2016–2021. The GHSS calls for the elimination of viral hepatitis as a public health threat by 2030 (reducing new infections by 90% and mortality by 65%.


News - Access to hepatitis C treatment in Europe: findings from the 2016 Hep-CORE study

While new direct-acting antivirals introduced are now effective enough to cure more than 90% of hepatitis C cases, it is not known whether there are suitable policies to promote access to treatment in European countries. The Hep-CORE study collected information on viral hepatitis policy issues from patient groups belonging to the European Liver Patients Association (ELPA) and offers insight into this situation.


Older news items can be found in the news archive.